Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study

Approximately 10 –20% of patients with gastroesophageal adenocarcinoma (GE-ADK) have HER2-positive tumors. The addition of trastuzumab to chemotherapy improves OS in patients with advanced disease. We investigated the effect of perioperative trastuzumab on survival outcomes.

Source: Digestive and Liver Disease - July 6, 2023 Category: Gastroenterology Authors: Anne-Esther Frydman, Antoine Drouillard, Emilie Soularue, Olivier Dubreuil, Aziz Zaanan, Anthony Turpin, David Tougeron, Sol ène Doat, Jean-Baptiste Bachet Tags: Oncology Source Type: research